Related Experiment Video

Updated: Jun 3, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors

Cynthia X Ma1, Robert J Crowder, Matthew J Ellis

  • 1Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. cma@dom.wustl.edu

Steroids
|March 23, 2011
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase (PI3K) pathway alongside endocrine therapy shows promise for hormone receptor-positive breast cancer, especially when PIK3CA mutations are present, overcoming endocrine resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Endocrine therapy is a primary treatment for hormone receptor-positive breast cancer, but resistance limits its effectiveness.
  • Activation of phosphatidylinositol 3-kinase (PI3K) signaling correlates with poor outcomes and endocrine resistance in luminal B breast cancer.
  • PIK3CA mutations are common in hormone receptor-positive breast cancer, creating dependency on PI3K pathway signaling.

Purpose of the Study:

  • To investigate the role of PI3K pathway signaling in endocrine-resistant breast cancer.
  • To explore the potential of inhibiting PI3K signaling to overcome endocrine resistance.
  • To provide a scientific rationale for targeting both estrogen receptor and PI3K pathways in ER+ breast cancer.

Main Methods:

  • Utilized endocrine-resistant breast cancer cell lines.
  • Inhibited PI3K pathway signaling.
  • Assessed the impact on cell survival and response to endocrine agents.
  • Examined synthetic lethality between estrogen deprivation and PI3K pathway inhibition.

Main Results:

  • Inhibition of PI3K pathway signaling reduced cell survival in endocrine-resistant breast cancer cell lines.
  • PI3K pathway inhibition improved treatment response to endocrine agents.
  • Synthetic lethality was observed between estrogen deprivation and PI3K pathway inhibition in ER+ breast cancer cell lines.

Conclusions:

  • Targeting the PI3K pathway is a viable strategy to overcome endocrine resistance in breast cancer.
  • Combined inhibition of estrogen receptor and PI3K pathways may improve outcomes for ER+ breast cancer patients.
  • PIK3CA mutations provide a specific target for this combined therapeutic approach.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...